Dynavax Technologies Corporation

2 results · Page 1 of 1

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Immunogenicity, Safety, and Tolerability of rF1V-1018 Vaccine in Adults 18 to 55 Years of Age	Prevention of Pneumonic Plague Resulting From Aerosol Exposure to Yersinia Pestis	Active, not recruiting	Phase 2	2026-10-05		NCT07207408
Safety and Immunogenicity of an Investigational Herpes Zoster Vaccine (Z-1018) Compared to Shingrix® in Healthy Adults 50 Years of Age and Over	DNA Virus Infections, Herpesviridae infectious disease, Infections, Vaccine-Preventable Diseases, Varicella Zoster Virus Infection, herpes zoster, viral infectious disease	Active, not recruiting	Phase 1 / Phase 2	2026-05-29		NCT06569823

Clinical trials